Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.
Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.
Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.
Testing appropriate patients with advanced non-small cell lung cancer (NSCLC) for ALK rearrangements and EGFR mutations is critically important to ensure delivery of the most effective lung cancer treatment.
Join Renato Martins, MD, MPH and Douglas Wood, MD as they present their multidisciplinary expertise on a range of cases pertaining to squamous cell lung cancer.
This recorded webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with non-small cell lung cancer.
This recorded webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with non-small cell lung cancer.
This recorded webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with non-small cell lung cancer.
Join Renato Martins, MD, MPH and Douglas Wood, MD as they present their multidisciplinary expertise on a range of cases pertaining to squamous cell lung cancer.
Facebook
X
LinkedIn
Forward